Research Analysts Offer Predictions for RCKT Q2 Earnings

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) - Research analysts at Leerink Partnrs increased their Q2 2025 earnings per share estimates for shares of Rocket Pharmaceuticals in a report released on Tuesday, May 27th. Leerink Partnrs analyst M. Foroohar now anticipates that the biotechnology company will post earnings per share of ($0.56) for the quarter, up from their prior forecast of ($0.57). Leerink Partnrs currently has a "Hold" rating on the stock. The consensus estimate for Rocket Pharmaceuticals' current full-year earnings is ($2.83) per share. Leerink Partnrs also issued estimates for Rocket Pharmaceuticals' Q3 2025 earnings at ($0.54) EPS, Q4 2025 earnings at ($0.52) EPS, FY2025 earnings at ($2.20) EPS, FY2026 earnings at ($1.94) EPS and FY2027 earnings at ($1.78) EPS.

Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.58) by $0.02. During the same period in the previous year, the company earned ($0.66) earnings per share.

A number of other equities analysts have also recently commented on RCKT. The Goldman Sachs Group cut Rocket Pharmaceuticals from a "neutral" rating to a "sell" rating in a report on Wednesday. Leerink Partners reissued a "market perform" rating and set a $8.00 price target (down from $37.00) on shares of Rocket Pharmaceuticals in a report on Wednesday. Chardan Capital decreased their price target on Rocket Pharmaceuticals from $46.00 to $17.00 and set a "buy" rating on the stock in a report on Wednesday. Morgan Stanley reissued an "equal weight" rating and set a $7.00 price target on shares of Rocket Pharmaceuticals in a report on Wednesday. Finally, Canaccord Genuity Group decreased their price target on Rocket Pharmaceuticals from $36.00 to $34.00 and set a "buy" rating on the stock in a report on Monday, May 12th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $21.21.

Rocket Pharmaceuticals Stock Performance

Rocket Pharmaceuticals stock traded down $0.14 during trading on Friday, reaching $2.48. The company had a trading volume of 7,402,317 shares, compared to its average volume of 1,878,766. Rocket Pharmaceuticals has a 52 week low of $2.19 and a 52 week high of $26.98. The firm's 50-day simple moving average is $6.20 and its 200 day simple moving average is $9.45. The firm has a market capitalization of $264.83 million, a price-to-earnings ratio of -0.90 and a beta of 1.02. The company has a current ratio of 6.05, a quick ratio of 6.05 and a debt-to-equity ratio of 0.06.

Hedge Funds Weigh In On Rocket Pharmaceuticals

A number of large investors have recently made changes to their positions in RCKT. Wellington Management Group LLP grew its holdings in shares of Rocket Pharmaceuticals by 24.5% during the fourth quarter. Wellington Management Group LLP now owns 13,995,177 shares of the biotechnology company's stock valued at $175,919,000 after buying an additional 2,753,033 shares during the last quarter. Suvretta Capital Management LLC purchased a new stake in shares of Rocket Pharmaceuticals during the fourth quarter valued at $32,267,000. Janus Henderson Group PLC grew its holdings in shares of Rocket Pharmaceuticals by 111.0% during the fourth quarter. Janus Henderson Group PLC now owns 4,004,039 shares of the biotechnology company's stock valued at $50,343,000 after buying an additional 2,106,699 shares during the last quarter. Point72 Asset Management L.P. grew its holdings in shares of Rocket Pharmaceuticals by 3,163.9% during the fourth quarter. Point72 Asset Management L.P. now owns 1,569,823 shares of the biotechnology company's stock valued at $19,733,000 after buying an additional 1,521,727 shares during the last quarter. Finally, Boxer Capital Management LLC purchased a new stake in shares of Rocket Pharmaceuticals during the fourth quarter valued at $18,428,000. 98.39% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Rocket Pharmaceuticals

In other Rocket Pharmaceuticals news, insider Kinnari Patel purchased 21,099 shares of Rocket Pharmaceuticals stock in a transaction dated Wednesday, April 9th. The shares were purchased at an average cost of $4.70 per share, for a total transaction of $99,165.30. Following the completion of the acquisition, the insider now owns 26,774 shares in the company, valued at $125,837.80. This represents a 371.79% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Aaron Ondrey sold 7,489 shares of Rocket Pharmaceuticals stock in a transaction that occurred on Friday, April 4th. The shares were sold at an average price of $5.29, for a total transaction of $39,616.81. Following the sale, the chief financial officer now directly owns 129,650 shares of the company's stock, valued at $685,848.50. This represents a 5.46% decrease in their position. The disclosure for this sale can be found here. Company insiders own 24.76% of the company's stock.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.